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1. Introduction 
Colorectal cancer (CRC) is the third most common cancer worldwide. Considering the high 
rate of incidence and mortality of CRC it is critical to determine the mechanisms of its 
dissemination. Although one of the better characterised tumours the prognosis of patients 
decreases dramatically when lymphatic metastasis occurs. In addition, the main important 
prognostic factor of CRC is the stage of tumour at the time of diagnosis, which is defined by 
the TNM system from the American Joint Committee on Cancer and the International Union 
Against Cancer. Therefore, during surgical treatment not only the primary tumour but also 
the draining lymph nodes have to be removed. From multivariate analysis it is known, that 
the number of examined lymph nodes is an independent prognostic factor. In this context, a 
prognostic relevance has been demonstrated not only for N0-, but also for N1- and N2-
status. Adjuvant chemotherapy is recommended for stage UICC III colon cancer. It has been 
shown to reduce tumour recurrence and improve overall survival (Schmiegel, Reinacher-
Schick et al. 2008). The five-year survival rate drops significantly from the UICC stage I to IV 
(Table 1). Patients with an early stage tumour (UICC I) have an excellent prognosis and a 
five-year survival rate of 90%, compared to those with advanced tumours and lymph node 
metastasis, who have a five-year survival rate of 30-60%. Patients with distant metastasis 
have a five-year survival rate below 10%.  
Thus the prognosis of CRC is significantly influenced by the occurrence of lymph node 
metastasis and in addition to its value as a prognostic indicator it also affects the 
therapeutically management of patients. The understanding of molecular mechanisms 
involved in lymphatic metastases may open the door for future treatment strategies. 
2. The lymphatic system 
2.1 Development of the lymphatic system 
Aspects of the lymphatic fluid and the associated transport system were already mentioned 
by the ancient Greeks, but it was poorly considered until the 17th century. In 1622 the Italian 
physician Gasparo Asselli re-identified lymphatic vessels as “milky veins” in the gut of a 
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Table 1. UICC stage and 5-year cancer related survival of patients with CRC.  
dog. The embryonic origin of lymphatic vessels remains further unclear. Since the beginning 
of the 20th century, two developmental theories -the centrifugal and the centripetal- have 
been controversial debated. The centrifugal theory by Sabin based upon dye and ink 
injection experiments in pigs. According to her view, lymphatic vessel formation occurs 
early during embryonic development from isolated primitive lymph sacs that originate from 
endothelial cells that bud from the veins. The peripheral lymphatic system originates from 
these primary lymph sacs by endothelial sprouting into the surrounding tissues and organs, 
where local capillaries are formed (Oliver and Detmar 2002). Simultaneously Huntington 
and McClure suggested an alternative model, the centripetal theory. In their opinion 
primary lymph sacs arise from mesenchymal precursor cells, independent of the veins and 
secondarily establish venous connections.  
To date, the development of the lymphatic vasculature system has not been ultimately 
resolved. Recent molecular analyses describe a polarized expression of the homeobox 
transcription factor Prox-1 in anterior cardinal vein endothelial cells, which is required for 
specification of lymphatic endothelial cells (LECs). Prox-1 is a master regulator which drives 
the transcription of a variety of genes whose expression is associated with key LEC 
characteristics (Tammela, Petrova et al. 2005). 
2.2 Structure and function of the lymphatic system 
The lymphatic vascular system is a hierarchical network comprising blind-ended capillaries, 
collecting vessels, lymph nodes, lymphoid organs and circulation lymphocytes. A number 
of important physiological functions have been described. It maintains fluid homeostasis by 
absorbing and draining e.g. interstitial fluids, plasma proteins and cells extravasated from 
blood vessels and returning them back into the blood circulation (Butler, Isogai et al. 2009). 
Furthermore, the lymphatic system is also known to be an important part of the body´s 
immunological surveillance system (Wiig, Keskin et al. 2010). Lymphatic vessels are 
distributed to most organs, with the exceptions of the central nervous system, bone marrow, 
cartilage, cornea and epidermis. Due to its dual role, fluid absorption and lymph transport, 
the structure of lymphatic vessels differ from blood vessels (Schulte-Merker, Sabine et al. 
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2011). Lymph capillaries are characterized by loose intercellular junctions, no or an 
incomplete basement membrane. The wall of lymphatic endothelial cells (LECs) is joined to 
the extracellular matrix by anchoring filaments. These filaments help the vessels open and 
function. Collecting lymphatic vessels consist of pericytes, which reduce lymphatic fluid 
extravasation and they are surrounded by smooth muscle cells (Figure 1) (Shayan, Achen et 
al. 2006).  
Tumour cells can take advantage of these structural characteristics to promote their 
dissemination to lymph nodes or other organs by the process of permeation into 
peritumoural lymphatics. In addition, LECs secrete chemotactic agents, which can attract 
tumours cells toward lymphatics, such as CCL21, whose receptor (CCR7) is expressed on 
some tumour cells (Shields, Emmett et al. 2007). Chemokines may mediate the tumour LEC 





Fig. 1. Structure of lymphatic vessels compared against blood vessels. The initial lymphatics 
have no or an incomplete basement membrane and no pericytes, which makes them suitable 
for the uptake of tumour cells. Anchoring filaments attach LECs to the extracellular matrix 
(ECM) and prevent vessel collapse.  
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Gene expression profiles of LECs and blood endothelial cells (BECs) have been analysed and 
compared (Figure 2). The most obvious differences were detected in genes coding for pro-
inflammatory cytokines/chemokines and their receptors, cytoskeletal and cell matrix 
organisation (Saharinen, Tammela et al. 2004). For example Interleukin (IL)-8, IL-6, the 
chemokine receptor CXCR4, ICAM-1, Integrin ┙5 are expressed in higher levels in the BECs. 
 
 
Abbreviations: Stat6 (signal transducer and activator of transcription 6), MCP-1 (monocyte chemotactic 
protein-1), IL-6/8 (Interleukin-6/-8), ICAM (intracellular adhesion molecule), Ang-1 (Angiopoietin-1), 
VEGF/ R ( Vascular endothelial growth factor/receptor), CD-44 (Cluster of Differentiation 44), IGF-1/2 
(Insulin like growth factor 1/2), FGF-2 (Fibroblast growth factor 2),  HGF (Hepatocyte growth factor),  
c-MET (mesenchymal epithelial transition factor), Tie-2 (angiopoietin receptor 2). Note that not all 
molecular markers are shown. 
Fig. 2. Molecular characteristics of BECs and LECs.  
3. Lymphangiogenesis  
3.1 Lymphangiogenesis and cancer metastasis 
Lymphangiogenesis takes place in a variety of physiological and pathophysiological 
processes, such as embryonic development, regeneration and wound healing on the one 
hand, and in lymph vascular malformations, inflammation and cancer on the other hand 
(Witte, Jones et al. 2006). Carcinogenesis is a complex multi-step process and despite the 
importance, that the lymphatic system provided one of the main routes for cancer 
progression, little information has been available about the molecular mechanisms by which 
the tumour cells gain access to the lymph system and are able to spread.  
Traditionally, lymphatic metastasis of tumours was considered to be a passive process, 
where tumour cells metastasized to lymph nodes by utilizing pre-existing lymphatic vessels 
via open junctions or that lymphatic vessel entry occurred by tumour eroding. The process 
of new lymphatic formation (lymphangiogenesis) does not occur.  
This view has been challenged (Achen and Stacker 2008). The identification of lymphatic 
specific markers, lymphangiogenic growth factors and their ligand receptor pathways, the 
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isolation of lymphatic endothelial cells and the development of specific in vitro culture 
systems in the past decades led to a broader understanding of the molecular mechanisms 
that control lymphatic metastasis.  
Yet there is mounting evidence that lymphangiogenesis does occur in tumours and that it 
promotes cancer progression. A shift in the balance between lymphangiogenic and anti-
lymphangiogenic signalling, like in the process of angiogenesis, might lead to 
lymphangiogenesis. Therefore a wide range of interactions at the tumour host interface have 
to take place, which support tumour proliferation, migration and survival. These processes 
are controlled by growth factors, adhesion molecules, fibroblasts, blood vessels, cytokines 
and chemo attractants (Figure 3) (Cueni and Detmar 2006; Ji 2006).  In the following section 
the most widely studied molecular mediators of lymphangiogenesis are reviewed.  
 
 
Fig. 3. Schematic overview of processes involved in tumour lymphangiogenesis and 
metastasis. Growth factors, cytokines, chemokines and tumour stroma contributes to 
tumour formation, growth, lymphangiogenesis and cancer progress. The tumour stroma 
consists of fibroblasts, ECM (extracellular matrix), blood vessels, lymphatic vessels and 
immune cells.  
3.2 Molecular players in tumour lymphangiogenesis 
3.2.1 Vascular endothelial growth factor 
The human VEGF family of growth factors includes VEGF-A, -B, -C, -D and placental 
growth factor (PIGF). They bind with different specificity to three tyrosine kinase receptors: 
VEGFR-1 (fms-like tyrosine kinase 1), VEGFR-2 (human kinase insert domain receptor), 
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VEGFR-3 (fms-like tyrosine kinase 4) and two non-protein kinase co-receptors (neuropilin-1 
and neuropilin-2). All VEGFRs have an extracellular binding region containing seven 
immunoglobulin-like domains (excepted VEGFR-3 who has only 6 domains), a single 
transmembrane helix and a conserved cytoplasmic domain that contains the catalytic core 
and regulatory sequences (Lohela, Bry et al. 2009). Activation of VEGFR by its ligands leads 
to receptor dimerization, autophosphorylation of tyrosine residues and initiation of 
signalling pathways (Roskoski 2008). 
VEGF-C, VEGF-D and their ligand VEGFR-3 were the first discovered and most exensively 
studied lymphangiogenic factors (Baldwin et al. 2002; Nagy et al. 2002). After activation of 
VEGFR-3 by its ligands, autophosphorylation of tyrosine residues results in binding of the 
signalling adaptor proteins Shc (adaptor protein p66), Grb-2 (growth factor receptor-bound 
protein) and in activation of the ERK 1/2 (extracellular signal regulated kinase) signal 
transduction cascade in a protein kinase C dependent manner and via PI3K-Akt  
(phosphatidylinositol 3-kinase protein kinase B) signalling cascade (Figure 4). Binding of the 
adaptor protein CRK 1/2 initiates the MKK4-JNK 1/2 (mitogen-activated protein kinase 
kinase 4- Jun N-terminal kinase) pathway and results in induction of c-JNK (c-Jun N-
terminal kinase) expression. The VEGFR-3 pathway mediates lymph endothelial growth, 
survival and migration (Wissmann and Detmar 2006). 
 
 
Fig. 4. The VEGF-C and VEGF-D pathways via VEGFR-3. Proteolytic processing, signal 
adaptor binding and activation of downstream signalling molecules results in lymph 
endothelial growth, proliferation and survival. 
There are several studies, which suggested a correlation between the expression level of 
VEGF-C and lymph node metastasis (LNM) in e.g. CRC, gastric, prostate, esophageal and 
www.intechopen.com
 
Molecular Mechanisms of Lymphatic Metastasis 291 
lung cancers (Achen and Stacker 2008). The mechanisms regulating the VEGF-C/VEGF-D 
expression in tumours are not fully revealed. It is known, that pro-inflammatory cytokines 
such as tumour necrosis factor (TNF) and Interleukins induce the expression of VEGF-C in 
tumour cells. The local ECM environment is assumed to trigger different VEGF receptors, 
resulting in signalling pathways which promote lymphangiogenesis.  
In fact, the results of some studies showed that the expression levels of VEGF-D and 
VEGFR-3 in colorectal carcinoma tissues are significantly higher than in normal tissues 
(Omachi, Kawai et al. 2007). Furthermore, recent reports have linked the VEGF-C/VEGF-D 
expression to lymphatic metastasis and poor patient outcome (Nagahashi, Ramachandran et 
al. 2010; Lin, Lin et al. 2011). Our histopathological examination also revealed that VEGF-C 
was present in CRC tissue, whereas the surrounding tissue was negative.   
 
 
Fig. 5. CRC immunohistochemically staining for VEGF-C expression. The strong VEGF-C 
expression appears in the colon carcinoma tissue, while the surrounding tissue is negative. 
VEGF-A is associated with angiogenesis, but it may also contribute to lymphangiogenesis. 
During angiogenesis VEGF-A induces proliferation and migration of endothelial cells, 
protease production and promotes cell survival. Fibroblasts, macrophages and endothelial 
cells are cells in the tumour microenvironment which are known to secrete VEGF-A. 
Evidence indicates that transforming growth factor ┙ (TGF) plays a role in regulating 
VEGF-A expression. The biological activity of VEGF-A is mainly mediated direct via 
activating of VEGFR-2 and indirectly by recruiting monocytes and neutrophils, which 
express VEGFR-1 and produce VEGF-C/VEGF-D.  
A number of reports describe in CRC a correlation between VEGF-A expression levels and 
lymph node metastasis (Sundlisaeter, Dicko et al. 2007).  
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3.2.2 Prox-1 
Prox-1 is a homeobox transcription factor. In several tissues, such as liver and pancreas 
Prox-1 is an important regulator of cell differentiation and oncogenesis. As mentioned 
before, the expression of Prox-1 is also essential for the lymphatic development and 
downstream signalling results in up-regulation of e.g. LYVE-1, VEGFR-3 and other 
lymphatic endothelial specific molecules.  
Prox-1 expression is revealed to be significantly increased in CRC (Parr and Jiang 2003). The 
precise function must be further clarified. 
3.2.3 Podoplanin 
Podoplanin is a 38-kDa single transmembrane mucin-type glycoprotein and in normal 
human tissue it is expressed e.g. by osteoblasts, kidney podocytes and lung alveolar type 1 
cells (Cueni, Hegyi et al. 2010). Due to its expression on lymphatic endothelial cells but not 
on blood vessels it is used as a specific marker for LECs.  
Under normal conditions podoplanin is involved in the regulation of the shape of 
podocytes, LV formation and it is supposed to be involved in platelet aggregation. The 
expression of podoplanin is regulated by Prox-1 (Raica, Cimpean et al. 2008). 
Since podoplanin expression is up-regulated in a number of different carcinomas such as 
vascular tumours, mesotheliomas and in squamous cell carcinomas, it is suggested that 
podoplanin is involved in carcinogenesis (Yamanashi et al. 2009). In addition, recent data in 
numerous of squamous cell carcinomas indicated that podoplanin is expressed at the 
invasive edge (Wicki and Christofori 2007). Podoplanin might favour tumour invasion via  
 
 
Fig. 6. Immunohistochemical detection of podoplanin positive lymphatic vessels, filled with 
cancer cells, in CRC. 
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its ability to remodel the cytoskeleton (Cueni, Hegyi et al. 2010). About the role of 
podoplanin in CRC little information is available. Lu et al. revealed, that the expression of 
podoplanin was significantly higher in patients with lymph node metastasis than in those 
without metastasis (Lu, Yang et al. 2007). While the group of Yamanashi suggested, that a 
positive podoplanin expression in stromal fibroblasts in patients with CRC is a significant 
indicator for a good prognosis (Yamanashi, Nakanishi et al. 2009). Figure 6 shows a 
lymphatic vessel stained with podoplanin and filled with a tumour cell embolus   
3.2.4 LYVE-1 
LYVE-1 is a homologue of the blood vascular endothelium specific hyaluronan receptor CD 
44 and accordingly a member of the Link protein family. CD44 is directly involved in 
leucocyte migration (Jackson 2009). Lyve-1 is one of the most specific and widely used 
lymphatic endothelial markers (Hirakawa 2011). During embryogenesis it is expressed in 
cardinal vein endothelium and is involved in vascular development. On LECs LYVE-1 is 
expressed on the luminal and ab-luminal surface and functional studies demonstrated that it 
is able to act as an endocytic receptor for hyaluronan (Al-Rawi, Mansel et al. 2005). 
Hyaluronan is an important component of the extracellular matrix with versatile features for 
the interaction of cells during embryogenesis and woundhealing. LYVE-1 is also expressed 
by sinusoidal endothelial cells in the liver, spleen and by macrophages. Its exact function 
remains unclear.  
3.2.5 Hepatocyte growth factor  
Hepatocyte growth factor (HGF) belongs to the plasminogen-prothrombin gene 
superfamily. C-Met, the HGF receptor is a tyrosine kinase receptor and composed of an 
extracellular ┙ chain and a transmembrane ┚ chain. HGF activity has been reported to play a 
role in embryogenesis and organogenesis (Lee et al. 2010).  
HGF is also supposed to be a potent lymphangiogenic factor. In this context HGF is 
involved in proliferation, migration, and tube formation of LECs (Cueni and Detmar 2006). 
The HGF downstream pathway is mediated via ERK 1/2 and PI3K and resulted in cell 
growth and inhibition of apoptosis. In many solid tumours c-Met is differently expressed. 
Novel investigations in CRC revealed an over expression of HGF and c-Met, and increased 
expression is associated with advanced disease stage and poor outcome (Kammula, Kuntz et 
al. 2007; Organ, Tong et al. 2011). 
3.2.6 Fibroblast growth factors 
The fibroblast growth factor family consists of structurally related ligands and four 
receptors (FGFR-1, FGFR-2, FGFR-3, FGFR-4), which consist the classical receptor tyrosine 
kinase structure: a extracellular Immunglobulin-like domain, a transmembrane domain and 
a intracellular tyrosine kinase domain, which initiated downstream signalling. The FGFs are 
involved in multi biological processes such as proliferation, survival, migration and 
differentiation during organogenesis and in adult life. A deregulation in human cancer has 
been found e.g. in breast cancer, prostate cancer, bladder cancer and cancer of the lung 
(Wesche, Haglund et al. 2011). FGF-2 is able to induce angiogenesis and lymphangiogenesis. 
Recent studies suggest that in LECs lymphangiogenic signalling is mediated through the 
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Akt-mammalian target of rapamycin (mTOR)-p70S6 kinase pathway (Matsuo, Yamada et al. 
2007). 
3.2.7 Angiopoietins 
Ang-1 and Ang-2 are the more intensive analysed members of the angiopoietin family.  Both 
bind to the Tie-2 receptor, which is expressed on the surface of LECs. The expression of 
Ang-1 and Ang-2 differs in human tissue. While Ang-1 is widely expressed in adult tissues, 
where it promotes vessel maturation and stabilization, Ang-2 expression occurs during 
vascular remodelling and via acting in conjugation with VEGF-A Ang-2 is supposed to be a 
stimulator of angiogenesis (Makinen, Norrmen et al. 2007).  
About the role and function of the angiopoietins Ang-1/Ang-2 in lymphangiogenesis little 
information is known. Ang-1 is involved in LEC proliferation and lymphatic vessel sprouting. 
From analysis of pancreatic cancer, we know that Ang-2 drives lymphatic metastasis via a Tie-
2 dependent manner and in a Tie-2 independent manner through enhancing the capacity of 
tumour cells for adherence to endothelial cells (Schulz, Fischer et al. 2011). 
3.2.8 Insulin like growth factors 
The insulin like growth factor system consists of the ligands insulin, insulin like growth 
factor 1 (IGF-1) and insulin like growth factor 2 (IGF-2) and acts via four receptors: the 
insulin receptor (IR), the type I IGF receptor, the type II IGF receptor and the hybrid IR/IGF-
1R receptor. The IGF-IR receptor consists of two ┙ and two ┚ chains. IGF-IR ligand binding 
induces multiple downstream signal transduction pathways such as the MAPK, ERK and 
PI3-K pathway. It is well known, that IGF family members are frequently expressed in many 
solid tumours like CRC and breast cancer (Werner, Roberts et al. 1996; Reinmuth, Liu et al. 
2002). In addition IGF-1R contributes to cancer development by regulation cell proliferation, 
differentiation and by preventing apoptosis. Other researchers investigated that IGF-1 and 
IGF-2 induce lymphangiogenesis (Bjorndahl, Cao et al. 2005) in a VEGFR-3 independent 
signalling pathway. 
3.2.9 Chemokines 
The chemokines, are a super family of chemotactic cytokines. They are key regulators of 
leukocyte, endothelial and epithelial cell migration and play a functional role in 
embryogenesis. Chemokines are low molecular weight proteins with cysteins at well 
conserved domains. According to the position of the cystein residue 4 chemokine 
subfamilies (CXC, CXC3, CC, C) have been identified so far. The chemokine CXCL12 is 
supposed to be involved in lymphogenesis via its receptor CXCR4 and CCL21 mediates 
homing of lymphocytes and migration of dendritic cells into lymphatic vessel.  
Nonetheless, it has been reported that chemokines and their receptors are expressed in a 
variety of human cancers such as melanoma, breast cancer, gastric cancer or prostate cancer 
(Hoon, Kitago et al. 2006). Recent findings about the direct role of chemokines in LNM in 
CRC, suggested an involvement of CXCR3, CXCL12/CXCR4 and CCL21/CCR7 (Kawada 
and Taketo 2011; Singh et al. 2011; Raman et al. 2010). In addition CXCL12 is supposed to be 
a prognostic factor for local recurrence and liver metastasis and CXCR4 expression was 
significantly positive in CRCs with high tumour stage and LNM. 
Taken together, Table 2 summarizes factors which are involved in lymphangiogenesis. 
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Factor Function during lymphangiogenesis 
VEGF-C/VEGF-D via VEGFR-3 
Growth factor/receptor:  
proliferation, migration, survival 
VEGF-A via VEGFR-2 
Activating VEGF-C/VEGF-D/VEGFR-3 signaling 
pathway 
Prox-1 Transcription factor: LEC identity 
Podoplanin Cell motility 
LYVE-1 Hyaluronan receptor 
HGF 
Growth factor:  
proliferation, migration, tube formation of LECs 
FGF LEC migration, proliferation 
Ang-1/2 Growth factor 
IGF 
Growth factor: proliferation,  
differentiation and preventing apoptosis 
Chemokines CCL21 Lymphocytes homing 
Table 2. Molecules which are involved in lymphangiogenesis 
3.3 Lymphatic vessel density and tumour progression 
Since, microvessel density (MVD), a parameter for the ability of angiogenesis in tumours, is 
a prognostic marker in numerous cancers, the quantification of lymphatic vessel density 
(LVD) is of growing interest. Screening the literature, the prognostic significance of LVD in 
tumours remains controversial (Royston and Jackson 2009). Some studies reported that high 
LVD was associated with lymph node metastasis and patient outcome, while others could 
not confirm these findings (Gao, Knutsen et al. 2009). Furthermore, there is a debate about 
the dominant role of intratumoural vs. peitumoural lymphatic vessels.  By some researchers  
it has been demonstrated that LVD in the intratumoural areas but not in peritumoural areas 
were associated with lymph node metastasis and poor outcome. Others reported that LVD 
in peritumoural areas was correlated to advanced tumour stage (Longatto-Filho, Pinheiro et 
al. 2008). In patients with colorectal cancer, a significant correlation between the number of 
intratumoural and peritumoural lymphatic vessels with the occurrence of lymph node 
metastases was evaluated (Matsumoto, Nakayama et al. 2007). These findings again 
underline the hypothesis of active lymphatic vessel formation within the tumour. These new 
lymphatic vessels may facilitate the drainage of tumour cells to regional lymph nodes. 
3.4 Future perspectives 
Further characterization of the exact molecular pathways which are involved in lymphatic 
metastasis is needed and essential for the development of new forecast estimates and 
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individually oriented therapies. Gene expression profiling by microarray technique, which 
allows the investigation of thousands of differentially expressed genes, provide therefore a 
promising tool to further clarify the molecular signature for lymphatic metastasis in CRC. 
These signatures can provide new players which are responsible for lymphatic metastasis or 
identify patients with a high risk for the development of lymph node metastases. New 
treatment targets could be evaluated and high risk patients can be selected for individual 
treatment regiments. (Croner, Peters et al. 2005; Croner, Fortsch et al. 2008; Croner, 
Schellerer et al. 2010).  
4. Conclusion  
Metastasis via tumour cell invasion into lymphatic vessels and lymph nodes is a common 
feature of various carcinomas. Our knowledge of the mechanisms controlling lymphatic 
metastasis has increased significantly in the last decades since the identification of LEC 
specific markers such as LYVE-1, podoplanin and Prox-1. The visualisation of the lymphatic 
system led to a new understanding of tumour activities involved in lymphatic vessel 
differentiation and growth. Take together, lymphangiogenesis is a complex multi step 
process, which is regulated by numerous molecular players and additional studies are 
needed to devise new and more efficient strategies against CRC.   
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